Kidney and Ureter Procedures for Neoplasm DRG 658 Reimbursement

DRG 658 encompasses kidney and ureter procedures performed for neoplasm without Complication or Comorbidity or Major Complication or Comorbidity, defining a lower-complexity surgical admission. It matters for inpatient reimbursement because Diagnosis-Related Group assignment determines standardized Medicare payment based on clinical case mix and documented resource intensity.

DRG 658 Overview

DRG 658 covers inpatient admissions for kidney and ureter surgical procedures performed for neoplasm when no Complication or Comorbidity and no Major Complication or Comorbidity are present. This Diagnosis-Related Group groups cases by clinical complexity and resource use to determine standardized Medicare payment for the hospitalization. It is important for hospitals because the classification affects base payment and impacts coding, billing, and expected reimbursement for urologic oncology surgeries. Accurate principal diagnosis and procedure coding determine assignment to this Diagnosis-Related Group and corresponding payment.

Perioperative randomized trials comparing minimally invasive nephrectomy techniques versus open surgery for localized renal neoplasm: These studies evaluate surgical approach (laparoscopic/robotic partial or radical nephrectomy versus open procedures) in adults with localized kidney tumors without significant comorbid complications, measuring intraoperative metrics, hospital length of stay, perioperative complications, and short-term oncologic outcomes. This research is relevant because surgical approach directly affects inpatient resource use, complication rates that drive CC/MCC classification, and reimbursement implications for DRG 658.
Comparative effectiveness studies of renal-sparing surgery versus radical nephrectomy in small renal masses focusing on functional and economic outcomes: Observational cohorts or pragmatic trials enrol patients with T1 renal neoplasms eligible for either partial nephrectomy or radical nephrectomy to compare postoperative renal function preservation, readmission rates, downstream dialysis risk, and total episode-of-care costs. Payers and providers need this evidence to balance immediate inpatient costs and longer-term morbidity that influence post-acute utilization and overall value of care under this DRG.
Post-discharge outcomes and survivorship studies assessing readmissions, complications, and health-related quality of life after kidney/ureter cancer surgery: Prospective registry-based or longitudinal cohort studies follow patients discharged after nephrectomy or ureteral tumor surgery to identify predictors of 30- and 90-day readmission, late surgical complications, surveillance adherence, and survivorship needs. These studies inform care pathways, discharge planning, and resource allocation because readmissions and complications alter inpatient case-mix, affect reimbursement patterns, and are key targets for cost and quality improvement for DRG 658.

Perioperative randomized trials comparing minimally invasive nephrectomy techniques versus open surgery for localized renal neoplasm: These studies evaluate surgical approach (laparoscopic/robotic partial or radical nephrectomy versus open procedures) in adults with localized kidney tumors without significant comorbid complications, measuring intraoperative metrics, hospital length of stay, perioperative complications, and short-term oncologic outcomes. This research is relevant because surgical approach directly affects inpatient resource use, complication rates that drive CC/MCC classification, and reimbursement implications for DRG 658.
Comparative effectiveness studies of renal-sparing surgery versus radical nephrectomy in small renal masses focusing on functional and economic outcomes: Observational cohorts or pragmatic trials enrol patients with T1 renal neoplasms eligible for either partial nephrectomy or radical nephrectomy to compare postoperative renal function preservation, readmission rates, downstream dialysis risk, and total episode-of-care costs. Payers and providers need this evidence to balance immediate inpatient costs and longer-term morbidity that influence post-acute utilization and overall value of care under this DRG.
Post-discharge outcomes and survivorship studies assessing readmissions, complications, and health-related quality of life after kidney/ureter cancer surgery: Prospective registry-based or longitudinal cohort studies follow patients discharged after nephrectomy or ureteral tumor surgery to identify predictors of 30- and 90-day readmission, late surgical complications, surveillance adherence, and survivorship needs. These studies inform care pathways, discharge planning, and resource allocation because readmissions and complications alter inpatient case-mix, affect reimbursement patterns, and are key targets for cost and quality improvement for DRG 658.

OpenPayer

Summary & Overview

Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

DRG 658 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes